Computed tomography guided interstitial percutaneous high-dose-rate brachytherapy in the management of lung malignancies. A review of the literature.
Brachytherapy
CT-guided
High dose rate
Lung cancer
Lung metastases
Journal
Brachytherapy
ISSN: 1873-1449
Titre abrégé: Brachytherapy
Pays: United States
ID NLM: 101137600
Informations de publication
Date de publication:
Historique:
received:
30
09
2020
revised:
01
03
2021
accepted:
19
03
2021
pubmed:
15
5
2021
medline:
12
10
2021
entrez:
14
5
2021
Statut:
ppublish
Résumé
A growing number of patients with lung cancer are not amenable to surgery due to their age or comorbidities. For this reason, local ablative techniques have gained increasing interest recently in the management of inoperable lung tumors. High-dose-rate percutaneous interstitial brachytherapy, performed under CT-guidance, is a newer form of brachytherapy and is a highly conformal radiotherapy technique. The aim of this study was to describe this method and review the existing literature. Eight articles comprising 234 patients reported toxicity and clinical outcome. The follow-up ranged from 6 to 28 months. Diverse fractionation schemes were reported, with 20 Gy in a single fraction being the most frequently utilized. Toxicity was limited; major pneumothoraces occurred after only 8% of the interventions. Local control rates at one year ranged between 37% and 91%. In conclusion, high-dose-rate percutaneous interstitial brachytherapy is a safe, fast, and efficient treatment option for inoperable lung tumors.
Identifiants
pubmed: 33985903
pii: S1538-4721(21)00061-1
doi: 10.1016/j.brachy.2021.03.012
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
892-899Informations de copyright
Copyright © 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.